Original Article · Originalarbeit
EU FP7 Project ‘CAMbrella’ to Build European Research Network for Complementary and Alternative MedicineWeidenhammer W.a · Lewith G.b · Falkenberg T.c · Fønnebø V.d · Johannessen H.e · Reiter B.f · Uehleke B.g · von Ammon K.h · Baumhöfener F.i · Brinkhaus B.j
a Competence Centre for Complementary Medicine and Naturopathy (KoKoNat), Klinikum rechts der Isar, Technische Universität, Munich, Germany, b Complementary and Integrated Medicine Research Unit, University of Southampton, UK, c Research Unit for Integrative Healthcare Research, Karolinska Institute, Stockholm, Sweden, d National Research Center on Complementary and Alternative Medicine (NAFKAM), University of Tromsø, Norway, e Institute of Public Health, Research Unit Health, Man and Society, University of Southern Denmark, Odense, Denmark, f International Academy for Holistic Medicine, Vienna, Austria, g Institute of Complementary Medicine, Dept. of Internal Medicine, University Hospital Zurich, h Institute of Complementary Medicine (KIKOM), University of Berne, Switzerland, i Bavarian Research Alliance, Munich, j Institute for Social Medicine, Epidemiology, and Health Economics, Charité – University Medical Center, Berlin, Germany
Dr. Dr. Wolfgang Weidenhammer, Kompetenzzentrum für Komplementärmedizin und Naturheilkunde (KoKoNat), Klinikum rechts der Isar, TU München, Kaiserstraße 9, 80801 München, Germany, firstname.lastname@example.org
Do you have an account?
Background: The status of complementary and alternative medicine (CAM) within the EU needs clarification. The definition and terminology of CAM is heterogeneous. The therapies, legal status, regulations and approaches used vary from country to country but there is widespread use by EU citizens. A coordination project funded by the EU has been launched to improve the knowledge about CAM in Europe. Objectives and Methods: The project aims to evaluate the conditions surrounding CAM use and provision in Europe and to develop a roadmap for European CAM research. Specific objectives are to establish an EU network involving centres of research excellence for collaborative projects, to develop consensus-based terminology to describe CAM interventions, to create a knowledge base that facilitates the understanding of patient demand for CAM and its prevalence, to review the current legal status and policies governing CAM provision, and to explore the needs and attitudes of EU citizens with respect to CAM. Based on this information a roadmap will be created that will enable sustainable and prioritised future European research in CAM. CAMbrella encompasses 16 academic research groups from 12 European countries and will run for 36 months starting from January 2010. The project will be delivered in 9 work packages coordinated by a Management Board and directed by a Scientific Steering Committee with support of an Advisory Board. Output: The outcomes generated will be disseminated through the project’s website, peer review open access publications and a final conference, with emphasis on current and future EU policies, addressing different target audiences.
© 2011 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.